Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
TOGA ASM 2026: Program Review
Apr 16, 2026
Unknown duration
ALK TKI Sequencing in the Australian Landscape
Apr 9, 2026
Unknown duration
Professor Michael Millward: Clinical Insights in Lung Cancer Research
Feb 26, 2026
Unknown duration
Dr. Megan Sanders: From Science to TOGA Leadership
Feb 12, 2026
Unknown duration
Lung Cancer Research: 2025 Year in Review
Jan 29, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4/16/26 |  TOGA ASM 2026: Program Review | In this episode of 'Conversations in Lung Cancer Research,' host A/Prof Surein Arulananda (Medical Oncologist, Monash Health) is joined by members of the Local Organising Committee to provide an exclusive preview of the 2026 TOGA Annual Scientific Meeting (ASM). The panel discusses the most anticipated sessions, emerging themes in thoracic oncology, and the evolving landscape of lung cancer care in Australia and New Zealand. | — | ||||||
| 4/9/26 |  ALK TKI Sequencing in the Australian Landscape | In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Tim Clay sits down with Australian oncology luminaries Prof Ben Solomon and A/Prof Malinda Itchins to discuss the rapidly evolving landscape of Anaplastic Lymphoma Kinase (ALK) positive lung cancer. Since its discovery in 2007, treatment for this subset of non-small cell lung cancer (NSCLC) has advanced through four generations of inhibitors, significantly improving survival outcomes for the 400–500 Australians diagnosed annually. | — | ||||||
| 2/26/26 |  Professor Michael Millward: Clinical Insights in Lung Cancer Research | In this episode of 'Conversations in Lung Cancer Research,' A/Prof Mel Moore talks with Prof Michael Millward, Foundation Professor of Clinical Cancer Research at the University of Western Australia and the oncology Medical Director at Linear Clinical Research in Perth. They discuss Prof Millward's extensive background in clinical and research interests in lung cancer and melanoma, the evolution of clinical trials, and the future of medical oncology, touching on molecular diagnostics, liquid biopsies, and early phase drug development. Millward also shares personal anecdotes and practical advice for young oncologists seeking to integrate clinical research into their careers. | — | ||||||
| 2/12/26 |  Dr. Megan Sanders: From Science to TOGA Leadership | In this episode of Conversations in Lung Cancer Research, host A/Prof Mel Moore interviews Dr. Megan Sanders, the Chief Executive Officer of TOGA. They discuss Megan's journey from working in vaccine formulation to earning a PhD in immunology, working in clinical trials, and eventually leading TOGA. They explore the challenges and achievements of TOGA, the importance of multidisciplinary engagement in lung cancer treatment, and the organisation's strategic plan for strengthening research and membership engagement. The conversation touches on the potential of clinical quality registries to improve patient care and highlights the ongoing effort to address the gaps in funding and equitable care for lung cancer patients. | — | ||||||
| 1/29/26 |  Lung Cancer Research: 2025 Year in Review | In this episode of 'Conversations in Lung Cancer Research,' hosted by A/Prof Mal Itchins, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Prof Nick Pavlakis from Royal North Shore Hospital and A/Prof Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the National Lung Cancer Screening Program (NLCSP), anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. This episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices. *This episode was recorded prior to the PBS update in December 2025. | — | ||||||
| 12/11/25 |  New and Emerging Practice Standards in ES-SCLC | In this episode of 'Conversations in Lung Cancer Research,' host Dr. Rebecca Tay and fellow oncologists A/Prof Surein Arulananda and Dr. Dasantha Jayamanne (DJ) delve into the latest advances in small cell lung cancer treatment. They explore new first-line treatments, including checkpoint inhibitors and emerging novel agents like lurbinectedin and tarlatamab, highlighting their mechanisms, survival benefits, and toxicity management. The panel also discusses the evolving role of radiotherapy and future directions involving precision medicine and biomarkers. This comprehensive discussion aims to inform clinicians and healthcare professionals about the promising advancements reshaping the small cell lung cancer treatment landscape. | — | ||||||
| 11/27/25 |  Exploring Lung Cancer Care and Research in New Zealand | In this episode of 'Conversations in Lung Cancer Research' hosted by Dr Alex Davis, features a discussion with Dr. Laird Cameron and Dr. Annie Wong on the current state of lung cancer care and research in New Zealand. The panel explores the challenges and disparities faced by thoracic cancer patients, particularly among the indigenous Māori population. The conversation highlights the differences between patient populations in New Zealand and Australia, the impact of rurality on cancer care, the importance of clinical trials and multinational collaborations, and the future prospects for lung cancer treatments and interventions. | — | ||||||
| 10/2/25 |  Challenging Ageism: Optimising Lung Cancer Treatment in Older Adults | In this episode of Conversations in Lung Cancer Research, hosted by Dr Michael Krasovitsky, a medical oncologist at St. Vincent's Hospital in Sydney, the focus is on lung cancer in older adults. The distinction and application of geriatric oncology are explored through comprehensive discussions with experts: A/Prof Christopher Steer, Prof Shalini Vinod, and Ms Nicole Webb. The conversation delves into the importance of geriatric assessments, the unique challenges faced by older patients undergoing cancer treatment, the impact of ageism, and the necessity of tailored, supportive care. Practical tools and approaches for assessing frailty, treatment decision making, and addressing the stigma surrounding lung cancer and aging are also detailed. The episode underscores the critical need for an open, compassionate, and holistic approach to cancer care in older populations. | — | ||||||
| 9/18/25 |  Prof. Anna Nowak: A Journey from Oncology Lab to Leadership | In this episode of Conversations in Lung Cancer Research, host A/Prof Mel Moore interviews Prof Anna Nowak, a renowned medical oncologist, clinical trialist, and tumour immunology researcher. We learn of Anna's early aspirations influenced by her family and mentors, her educational and professional trajectory, and her transition to a leadership role as Deputy Vice Chancellor at the University of Western Australia. Anna shares insights on the challenges and rewards of juggling clinical practice with research, her contributions to mesothelioma studies, involvement in the DREAM and DREAM3R trials, and her role in mentoring the next generation of oncologists. | — | ||||||
| 9/4/25 |  CNS Progression in Lung Cancer: A Practical Conversation on Best Practices | n this episode of Conversations in Lung Cancer Research, A/Prof Tim Clay discusses the multidisciplinary management of CNS metastases in the context of thoracic cancers. Joined by Dr. Keryn Davidson, a consultant neurosurgeon, and A/Prof Fiona Hegi Johnson, a radiation oncologist, the discussion focuses on the nuances of treating patients with non-small cell lung cancer presenting with brain metastases. Key topics include the role of neurosurgery, decision-making for radiation therapy, evolving approaches for oncogene-driven cancer patients, management of radiation necrosis, and the complexities of treating small cell lung cancer and leptomeningeal disease. This episode is sponsored by Pfizer. | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 8/14/25 |  A/Prof Fiona Hegi Johnson: Navigating Careers and Innovations in Lung Cancer Research | In this episode of 'Conversations in Lung Cancer Research,' A/Prof Mel Moore sits down with A/Prof Fiona Hegi Johnson, a radiation oncologist at the Peter McCallum Cancer Center and senior research fellow at the University of Melbourne. Fiona shares her journey into radiation oncology, highlighting her career progression, the impact of serendipity, and the importance of mentors. They discuss technological advancements in the field, the role of multidisciplinary teams, changes in lung cancer treatments, and clinical challenges. Fiona offers insights into balancing clinical work with research and provides advice for early-career professionals in the field. | — | ||||||
| 7/10/25 |  Prof Shankar Siva: Pushing Boundaries in Radiation Oncology | In this episode of TOGA's Conversations in Lung Cancer Research, A/Prof Mel Moore speaks with Prof Shankar Siva about his groundbreaking work in radiation oncology, particularly focusing on the PRIME Lung study. They discuss the journey from concept to large clinical trials, the challenges of grant applications, the importance of controversial ideas in research, and the role of industry funding. Shankar also shares insights into his interest in genitourinary cancers and the future of radiation therapy, emphasising the significance of mentorship and practical advice for junior radiation oncologists. | — | ||||||
| 6/19/25 |  The Emerging Role of the Microbiome in Lung Cancer and Immunotherapy Response | This episode of 'Conversations in Lung Cancer Research' features Dr. Anna McLean, Dr Mark Adams, and Dr Sagun Parakh, discussing research on the microbiome and its influence on lung cancer treatment outcomes. They delve into the differences between the gut and lung microbiomes, methods for studying these microorganisms, and the potential for the microbiome to serve as biomarkers for treatment response and immune-related adverse events. They also cover the importance of collaboration and larger data sets in advancing this promising area of research. | — | ||||||
| 6/5/25 |  Lessons from Fellowships and building Clinical Trials Units | In this episode of Conversations in Lung Cancer Research, we welcome A/Prof Bryan Chan, a senior Medical Oncologist and this years TOGA ASM Convener. Bryan, affiliated with multiple institutions including Adam Crosby Cancer Center and Griffith University, discusses his comprehensive career journey from fellowship at the Princess Margaret Cancer Center in Toronto to his current roles in Australia. The discussion highlights the benefits of overseas fellowships, the development of clinical trials, and his leadership in thoracic oncology at the Sunshine Coast University Hospital. Bryan also touches upon the challenges and rewards of balancing private and public practice and pioneering quality improvement initiatives. The episode concludes with an exciting preview of the upcoming TOGA Annual Scientific Meeting, which Bryan is convening. Medical professionals and anyone interested in the latest in lung cancer research and practice will find valuable insights in this conversation with Bryan. | — | ||||||
| 5/21/25 |  Prof Wendy Cooper: Journey of a Thoracic Pathologist | In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore speaks with Prof Wendy Cooper, a leading pathologist in cancer research. They discuss Wendy's journey into pathology, the evolution of lung cancer diagnostics, the impact of AI and liquid biopsies, and the importance of international collaboration in research. Wendy shares insights on the challenges of equitable access to cancer diagnostics and the pressures faced by pathologists in multidisciplinary meetings. The conversation concludes with advice for junior clinicians on career development and involvement in professional organisations. | — | ||||||
| 5/8/25 |  Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy | In this episode of 'Conversations in Lung Cancer Research,' Professor Tom John from the Peter MacCallum Cancer Centre in Melbourne discusses the significant progress and excitement surrounding cancer vaccines, particularly their emerging role in lung cancer treatment. He is joined by Professor Ken O'Byrne, a medical oncologist and clinical scientist at the Princess Alexandra Hospital and Queensland University of Technology, and Professor Georgina Long AO, the medical director of the Melanoma Institute of Australia and co-recipient of the 2024 Australian of the Year. The experts delve into technological advances spurred by COVID-19 vaccine development, promising results from recent melanoma and lung cancer vaccine trials, and the potential for personalised neoantigen mRNA vaccines. They also discuss historical challenges in vaccine efficacy and the promising future of immunotherapy and cancer vaccines, including patient perspectives and the logistics of rapid vaccine production and distribution. | — | ||||||
| 3/20/25 |  The Role of Liquid Biopsy in Modern Oncology | In this episode of Conversations in Lung Cancer Research, Dr. Malinda Itchins, Dr. Annie Wong, and A/Prof Stephen Kao discuss the concept of liquid biopsy, its advantages and limitations, and its clinical applications in lung cancer treatment. They explore how liquid biopsy can provide faster diagnosis and treatment options, especially for patients who cannot undergo traditional tissue biopsies. However, they also address the challenges of sensitivity and the need for further research to integrate liquid biopsy into routine clinical practice. This episode is sponsored by: AstraZeneca Daiichi Sankyo Australia SOPHiA Genetics Thermo Fisher Scientific | — | ||||||
| 3/6/25 |  Exploring EGFR Exon 20 Insertion Mutations | In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into the characteristics, detection, and treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. The podcast discusses recent advances, the efficacy of various treatments including small molecule tyrosine kinase inhibitors and monoclonal antibodies, and the potential future of targeted therapies. Special focus is given to the Phase 3 Papillon study and the drug Amivantamab, highlighting the need for next generation sequencing in clinical settings. Key challenges and questions in the field are also addressed, including the impact of co-mutations and optimal therapy sequencing. | — | ||||||
| 2/5/25 |  From Clinical Research to Leadership: A Conversation with Prof. Michael Boyer | In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore interviews Prof Michael Boyer, AM about his extensive career in medical oncology and his current role as CEO of Chris O'Brien Lifehouse. They discuss his early interest in oncology, the influential mentors in his career, and the evolution of lung cancer treatment and research. Michael shares his perspectives on leadership in medical and research roles, the importance of building relationships, and the balance between industry-sponsored and cooperative group research. They also touch upon professional challenges, emotional resilience in oncology, and Michael's vision for the future of his career and the field of oncology. | — | ||||||
| 2/4/25 |  Introducing Conversations in Lung Cancer Research - Trailer | In this introductory episode, Associate Professor Mel Moore, medical oncologist and education chair at TOGA, announces the evolution of TOGA podcasts to 'Conversations in Lung Cancer Research.' The podcast will continue to deliver the latest breakthroughs in lung cancer research while expanding to include deeper dives and engaging discussions with experts in thoracic oncology. Listeners can look forward to unique insights from researchers, clinicians, and key thought leaders shaping the future of lung cancer care. | — | ||||||
| 12/12/24 |  Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy | We have witnessed incredible advances in therapy since ALK was discovered in 2007, starting from the pivotal PROFILE 1001 study of crizotinib in advanced ALK positive NSCLC to present day where we now have five approved targeted agents, with increasing potency, selectivity and CNS activity with each successive generation of drug. Despite these advances in therapy, the emergence of treatment resistance in the TKI still remains one of greatest challenges in the clinic. Our TOGA podcast panel discuss the clinical and genetic factors affecting treatment choice, sequencing and resistance patterns, including oligoprogression and local therapy considerations. Dr Rebecca Tay, Medical Oncologist at Royal Hobart Hospital and ICON Hobart, is joined in this discussion by Professor Ben Solomon, Medical Oncologist at Peter MacCallum Cancer Centre & Board member, Scientific Chair of TOGA and Associate Professor Michael Ng, Radiation Oncologist at GenesisCare St Vincents Hospital Melbourne and Head of Stereotactic Radiotherapy at GenesisCare Victoria. References: CROWN: ascopubs.org/doi/10.1200/JCO.24.00581 Gomez paper denovo oligomet SABR pubmed.ncbi.nlm.nih.gov/31067138/ Kroeze – concurrent systemic therapy + SABR consensus sciencedirect.com/science/article/abs/pii/S1470204522007525 Tsai Curb trial RCT for oligoprogression pubmed.ncbi.nlm.nih.gov/38104577/ Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube: https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present. | — | ||||||
| 12/2/24 |  Hit It With Your Best Shot- The Case for IO in Early-Stage NSCLC in a Once in a Lifetime World | Our latest podcast explores the case for IO in early-stage NSCLC in our once in a lifetime world – the current Australian context. We review the medical oncology and surgical perspective of the current evidence for clinical benefit and what we have available in Australia. As clinicians, we are trained to give our best treatment up front, so patient discussion is important in an environment where we can only prescribe IO therapy once during the patient’s lung cancer disease. Dr Deme Karikios, Medical Oncologist from Nepean Hospital and Co-Chair of the Oncology Drugs Working Group is joined by Dr Lauren Brown, Medical Oncologist and Research Fellow at Nepean, Blacktown & Westmead Hospitals and Dr Stephen Barnett, Cardiothoracic Surgeon at the Austin Hospital, Peter MacCallum, Royal Melbourne and Western General Hospitals. CheckMate816: https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 IMpower010: https://www.annalsofoncology.org/article/S0923-7534(23)00764-0/fulltext Neotorch: https://jamanetwork.com/journals/jama/fullarticle/2813880 Keynote671: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01756-2/abstract AGEAN: https://www.nejm.org/doi/full/10.1056/NEJMoa2304875 CheckMate770: https://www.nejm.org/doi/full/10.1056/NEJMoa2311926 | — | ||||||
| 11/14/24 |  Large-Cell Neuroendocrine Carcinoma of the Lung (LCNEC): Challenges in Diagnosis and Treatment | In this episode, we discuss the clinical and diagnostic markers when identifying a rare sub type of NSCLC, large-cell neuroendocrine carcinomas (LC-NEC), and provide insights into the management of these patients and future treatment developments. Associate Professor Rachel Wong, Deputy Director Oncology Eastern Health and Medical Oncologist at Epworth East in Melbourne is joined by Dr Patrick Hosking, Senior Histopathologist at Eastern Health Pathology; Dr Mal Itchins, Thoracic Medical Oncologist at Royal North Shore Hospital and Chris O'Brien LifeHouse in Sydney and Dr Sagun Parakh, Medical Oncologist at the Austin Hospital, Lung Cancer Lead. https://www.omico.com.au/our-programs/cancer-screening-program-casp/ Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube: https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present. | — | ||||||
| 9/30/24 |  Management of Limited-Stage Small Cell Lung Cancer (LS-SCLC) | In this episode, we dive into the latest survival data from the ADRIATIC trial, as presented at ASCO 2024, which could change the treatment landscape for LS-SCLC. Joining us are leading experts in oncology Zarnie Lwin, Susan Harden and Wei-Sen Lam. Together, they explore the significance of the ADRIATIC trial results, debate the role of prophylactic cranial irradiation (PCI) in the treatment of SCLC, and provide insights into ongoing studies that may further improve outcomes for patients. Tune in for a deep dive into the latest research and expert perspectives on this aggressive cancer. Podcasters: Associate Professor Zarnie Lwin, OAM, Medical Oncologist at Royal Brisbane Women’s Hospital and the University of Queensland, QLD Associate Professor Susan Harden, Radiation Oncologist at Peter MacCallum Cancer Centre and Monash Cancer Registries, VIC Dr. Wei-Sen Lam, Medical Oncologist and TeleHealth lead at Fiona Stanley and Esperance Hospitals, WA | — | ||||||
| 8/30/24 |  NTRK1, 2,3 And Other Rare Mutations In NSCLC | In this TOGA podcast, we provide an overview of the treatment options for rare subtypes of oncogene driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2,3 and other rare mutations in NSCLC. The importance of testing all patients is discussed as well as what to do when resistance occurs. Associate Professor Steven Kao, Medical Oncologist from Chris O’Brien Lifehouse and Clinical Associate Professor Sydney Medical School, Faculty of Medicine and Health is joined by Professor Wendy Cooper, senior staff specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, Anatomical Clinical Stream Lead for NSW Health Pathology, a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney and also Professor Ben Solomon head of the lung Medical Oncology Service and a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division at Peter MacCallum Cancer Centre as well as a Founding Board member of TOGA. Support TOGA Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify. --------------- Connect with TOGA Attend an Event: https://thoraciconcology.org.au/events/ Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/ Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/ Follow Us LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/ X (Twitter): https://x.com/TOGAANZ Instagram: https://www.instagram.com/togaanz/ YouTube: https://www.youtube.com/@Thoracic_Oncology --------------- Acknowledgement of Country The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present. | — | ||||||
Showing 25 of 66
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.